New Study Shows Consistent Medical-Grade Accuracy and Environmental Benefits to Replacing Mercury Sphygmomanometers with OMRON HEM-907XL

A peer-reviewed, published study by the National Center for Health Statistics and supported by the CDC comparing manual and electronic blood pressure monitors demonstrated that medical professionals could replace the mercury sphygmomanometer traditionally used in physician offices with an automated monitor such as the OMRON HEM-907XL and maintain consistent medical-grade accuracy. Researchers found the OMRON HEM-907XL matched the accuracy of mercury sphygmomanometers and concluded that making the switch to the automated blood pressure monitor could reduce and eliminate the presence of mercury in blood pressure monitors, and achieve environmental benefits and cost effectiveness for medical practices.

“OMRON blood pressure monitors are reviewed by the FDA, cleared as medical devices, and rank as the number one brand among physicians and pharmacists. This new study is a testament to the accuracy and reliability of our medical devices,” said Jim Li, executive director, Global Medical Affairs for OMRON Healthcare. “This study highlights the opportunity for medical professionals and benefits the environment by replacing the mercury sphygmomanometer.”

The test group was comprised of 4,477 eligible participants over a one-year period with ages ranging from 18 through 60 and over. Within the test group, blood pressure was measured using two protocols – the auscultation protocol (AP) administered by a physician using a mercury sphygmomanometer and the oscillometric protocol (OP) administered by a health technician using an OMRON HEM-907XL device – in a randomly assigned order. Between-protocol, mean systolic BP and diastolic BP measurements were compared. Then, the prevalence of stage 1 high blood pressure was determined, and protocols were evaluated.

Results showed that although mean systolic BP and diastolic BP obtained by AP and OP differed, the prevalence of stage 1 high blood pressure did not differ, suggesting that a change in protocol may not affect blood pressure prevalence estimates.
This research adds to a body of established science on OMRON’s HEM-907XL, which is clinically validated for accuracy and designed for use in a professional setting including a physician’s office, hospital, or other point of care environment. For more information on OMRON’s HEM-907XL or Professional Intellisense® Blood Pressure Monitor, visit

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy